Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6 vs 12 Months of Trastuzumab + Docetaxel Following FE75C in HER2+ Breast Cancer
NCT00615602Phase 3Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Oct 2004
- Primary completion
- May 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Hellenic Oncology Research Group. Started Oct 2004; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00615602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00615602.